Company news
Biocardia, Inc. (NASDAQ:BCDA) news
Every Biocardia, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for...
August 24, 2026
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
August 12, 2026
BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
August 5, 2026
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
June 18, 2026
BioCardia Announces $4.4 Million Financing
June 8, 2026
BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart F...
May 28, 2026
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Toler...
May 21, 2026
BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
May 19, 2026
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
May 15, 2026
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
May 11, 2026
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
May 8, 2026
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navi...
April 28, 2026
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
April 20, 2026
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
April 2, 2026
BioCardia Reports 2025 Business Highlights and Financial Results
March 24, 2026
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
March 19, 2026
BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA
March 17, 2026
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (...
March 3, 2026
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Deliver...
February 10, 2026
BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure The...
February 3, 2026
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
December 16, 2025
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno
December 3, 2025
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress
December 1, 2025
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
November 24, 2025
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
November 12, 2025
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
November 10, 2025
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
November 5, 2025
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
October 30, 2025
BioCardia Regains Compliance with Nasdaq Listing Requirements
October 2, 2025
BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Is...
September 22, 2025
BioCardia Announces Pricing of Up To $12 Million Public Offering
September 18, 2025
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduc...
September 18, 2025
BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
September 4, 2025
BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology
August 13, 2025
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results
August 11, 2025
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
August 6, 2025
BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for ...
August 4, 2025
BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Isch...
July 24, 2025
Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejectio...
July 16, 2025
BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System
June 25, 2025
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
May 21, 2025
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results
May 14, 2025
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
May 9, 2025
BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study
May 6, 2025
BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell ...
May 1, 2025
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial
April 15, 2025
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
April 11, 2025
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
March 31, 2025
Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac ...
March 31, 2025
BioCardia Reports 2024 Business Highlights and Financial Results
March 26, 2025